Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AC Immune S.A.
(NQ:
ACIU
)
3.480
-0.150 (-4.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
88,092
Open
3.590
Bid (Size)
3.410 (2)
Ask (Size)
3.890 (1)
Prev. Close
3.630
Today's Range
3.440 - 3.590
52wk Range
2.200 - 5.140
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024
From
AC Immune SA
Via
GlobeNewswire
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Performance
YTD
-25.80%
-25.80%
1 Month
-14.91%
-14.91%
3 Month
+47.46%
+47.46%
6 Month
-16.14%
-16.14%
1 Year
+19.18%
+19.18%
More News
Read More
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
May 31, 2024
Via
Benzinga
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
May 28, 2024
From
AC Immune SA
Via
GlobeNewswire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
May 23, 2024
Via
Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Gold Down Over 1%; AC Immune Shares Spike Higher
May 13, 2024
Via
Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Via
Benzinga
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 13, 2024
Via
Benzinga
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
May 13, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
May 13, 2024
Via
InvestorPlace
Why Is Safe & Green Development (SGD) Stock Down 5% Today?
May 13, 2024
Via
InvestorPlace
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
Via
InvestorPlace
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
March 14, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
February 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
January 22, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
January 03, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Raises $50M, Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial
December 15, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.